| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Rhamnetin targets multiple pathways involved in oxidative stress and inflammation. Its mechanism of action involves scavenging free radicals, inhibiting oxidative stress at the molecular level. It also modulates the activity of pro-inflammatory enzymes and cytokines, thereby exerting anti-inflammatory properties. It inhibits secretory phospholipase A2.
|
|---|---|
| ln Vitro |
In vitro, Rhamnetin demonstrates significant antioxidant and anti-inflammatory activities. It scavenges free radicals and inhibits oxidative stress. It modulates the activity of pro-inflammatory enzymes and cytokines. It inhibits secretory phospholipase A2. It also induces apoptosis and cell cycle arrest in certain cancer cells.
|
| ln Vivo |
In vivo, Rhamnetin is believed to contribute to the health benefits of plants that contain it. Its antioxidant and anti-inflammatory properties suggest potential benefits for various health conditions, including cancer, cardiovascular disease, and neurodegenerative disorders. Specific standalone in vivo data for this compound are limited.
|
| Enzyme Assay |
The in vitro antioxidant assay for Rhamnetin involves measuring its ability to scavenge free radicals, such as DPPH or ABTS. The compound is incubated with the radical, and the decrease in absorbance is measured. For anti-inflammatory activity, its ability to inhibit the production of inflammatory mediators, such as nitric oxide or prostaglandins, in stimulated macrophages is measured.
|
| Cell Assay |
In vitro cell culture studies for Rhamnetin utilize various cell lines to study its bioactivity. Its anticancer activity is assessed in cancer cell lines using MTT assays. Its anti-inflammatory effects can be studied in macrophage cell lines by measuring cytokine production. Its antioxidant effects can be studied by measuring its ability to reduce ROS levels in cells. Its ability to induce apoptosis and cell cycle arrest is assessed by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for Rhamnetin are not extensively documented. However, its antioxidant and anti-inflammatory effects could be studied in rodent models of inflammation or oxidative stress. The compound would be administered orally or intraperitoneally, and endpoints such as inflammatory cytokine levels, tissue damage, and oxidative stress markers would be assessed.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of rhamnosine include (2S,3S,4S,5R)-6-[2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxacyclohexane-2-carboxylic acid. Rhamnetin has a molecular formula of C16H12O7 and a molecular weight of 316.26 g/mol. It is a solid compound that is soluble in organic solvents like DMSO. It is typically stored as a powder at 2-8°C for long-term stability. Its stability is maintained under recommended storage conditions. It is a light green to light yellow solid. |
| Toxicity/Toxicokinetics |
Toxicological data for Rhamnetin are limited, as it is a research compound. As a natural flavonoid, it is generally considered to have low toxicity. However, as a research compound, it is not intended for human therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Rhamnin is a monomethoxyflavonoid, a product of quercetin methylated at the 7-position. It possesses metabolic, antioxidant, and anti-inflammatory effects. It is a monomethoxyflavonoid and tetrahydroxyflavonoid, functionally related to quercetin, and is the conjugate acid of rhamnin-3-ol salt. Rhamnin has been reported to be found in tea (Camellia sinensis), watercress (Ammannia multiflora), and other organisms with relevant data.
Rhamnetin is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of flavonoids and their potential applications in oxidative stress, inflammation, and cancer. Its antioxidant, anti-inflammatory, and anticancer properties make it a compound of interest for research into various diseases. |
| Molecular Formula |
C16H12O7
|
|---|---|
| Molecular Weight |
316.2623
|
| Exact Mass |
316.058
|
| CAS # |
90-19-7
|
| PubChem CID |
5281691
|
| Appearance |
White to yellow solid powder
|
| Density |
1.634g/cm3
|
| Boiling Point |
627.9ºC at 760 mmHg
|
| Melting Point |
293-296°C (dec.)
|
| Flash Point |
238.9ºC
|
| Index of Refraction |
1.74
|
| LogP |
2.291
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JGUZGNYPMHHYRK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O7/c1-22-8-5-11(19)13-12(6-8)23-16(15(21)14(13)20)7-2-3-9(17)10(18)4-7/h2-6,17-19,21H,1H3
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1620 mL | 15.8098 mL | 31.6196 mL | |
| 5 mM | 0.6324 mL | 3.1620 mL | 6.3239 mL | |
| 10 mM | 0.3162 mL | 1.5810 mL | 3.1620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
